Grifols
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary, Public
- Established
- 1940-01-01
- Employees
- 23.7K
- Market Cap
- $6.8B
- Website
- http://www.grifols.com
- Introduction
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products an...
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 174
- Registration Number
- NCT01222117
- Locations
- 🇺🇸
Kaleida Health System, Buffalo, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇧🇪Ziekenhuis Oost Limburg, Campus St. Jan, Genk, Limburg, Belgium
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
- Conditions
- Interventions
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01213043
- Locations
- 🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Temple University Hosptial/Temple Lung Center, Philadelphia, Pennsylvania, United States
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 40
- Registration Number
- NCT01014975
- Locations
- 🇷🇸
Clinical Center Niš, Center of Radiology, Niš, Serbia
🇷🇸Clinical Center of Vojvodina, Center for Radiology, Novi Sad, Serbia
🇦🇹O.O. Landes-Nervenklinik Wagner-Jauregg, Linz, Upper Austria, Austria
Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 72
- Registration Number
- NCT00486837
Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels
- Conditions
- Interventions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00437671
- Locations
- 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States
A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion
- Conditions
- Interventions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 83
- Registration Number
- NCT00418483
- Locations
- 🇺🇸
Jobst Vascular Institute, Toledo, Ohio, United States
A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency
- Conditions
- Interventions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 35
- Registration Number
- NCT00389324
- Locations
- 🇨🇦
McGill University - Montreal General Hospital, Montreal, Quebec, Canada
🇨🇦Dr. Donald F. Stark, Inc, Vancouver, British Columbia, Canada
🇺🇸University of California, Irvine, Irvine, California, United States
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
- Conditions
- Interventions
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 38
- Registration Number
- NCT00301366
- Locations
- 🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇬🇧University of Cambridge - Cambridge Institute for Medical Research, Cambridge, England, United Kingdom
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00295061
- Locations
- 🇺🇸
National Jewish Medical and Research Center, Denver, Colorado, United States
🇺🇸St Lukes-Roosevelt Hospital Center, New York, New York, New York, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
- Conditions
- Interventions
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00263887
- Locations
- 🇩🇰
Gentofte Hospital Department of Respiratory Medicine, Hellerup, Denmark
🇸🇪Department of Pulmonary Medicine, Malmö University Hospital, Malmö, Sweden
🇬🇧Queen Elizabeth Hospital, Birmingham, England, United Kingdom